ArticleTherapeutic advances in gastroenterology2017
Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals.
Article in Therapeutic advances in gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 59 citations in OpenAlex.
- Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open-label, single-center, pilot clinical trial.Journal of general and family medicine · 2024Article
- Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.Pharmacological reports : PR · 2024Article
- Article
- Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.World journal of hepatology · 2022Review
- Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs.Scientific reports · 2021Article
- Alanine aminotransferase and spleno-portal dynamics affect spleen stiffness measured by point shear-wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis.Journal of ultrasound · 2021Article
- Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease.Gastroenterology research and practice · 2021Article
- Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals.Hepatology forum · 2020Article
- The Importance of Transaminases Flare in Liver Elastography: Characterization of the Probability of Liver Fibrosis Overestimation by Hepatitis C Virus-Induced Cytolysis.Microorganisms · 2020Article
- Spleen stiffness to liver stiffness ratio significantly differs between ALD and HCV and predicts disease-specific complications.JHEP reports : innovation in hepatology · 2019Article
- Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.BMC gastroenterology · 2019Article
- Hepatitis C Pretreatment Profile and Gender Differences: Cognition and Disease Severity Effects.Frontiers in psychology · 2019Article
- Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients.World journal of hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to investigate the early changes in liver and spleen stiffness measurement (LSM, SSM) in hepatitis C virus (HCV) patients with compensated advanced chronic liver disease (cACLD) treated with new antivirals (DAA) to elucidate factors determining the initial change in stiffness and its implications for the long-term follow up of HCV-cured patients.
methodsA total of 41 patients with cACLD who started DAA therapy underwent LSM and SSM at baseline, week 4, end of treatment (EOT), 24 and 48 weeks of follow up using transient elastography.
resultsLSM improved rapidly during the first 4 weeks of treatment (baseline: 20.8kPa; week 4: 17.5kPa,
conclusionsLSM and SSM decrease very rapidly during DAA treatment in cACLD patients suggesting that it most probably reflects a reduction in inflammation rather than in fibrosis. cACLD patients should be maintained under surveillance independently of stiffness changes, because advanced fibrosis can still be present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.